Pfizer reaches a global agreement with AbbVie
Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under the terms of the agreements, AbbVie grants Pfizer a non-exclusive patent license for the use and sale of Pfizer's proposed adalimumab biosimilar for many countries around the world. (Source: World Pharma News)
Source: World Pharma News - December 4, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

AbbVie Announces HUMIRA(R) (adalimumab) Global Patent License with Pfizer
NORTH CHICAGO, Ill., Nov. 30, 2018 -- (Healthcare Sales & Marketing Network) -- AbbVie (NYSE: ABBV) announced today patent license agreements with Pfizer over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant... Biopharmaceuticals, Generics, Licensing AbbVie, Pfizer, biosimilar, HUMIRA, adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 30, 2018 Category: Pharmaceuticals Source Type: news

NHS ditches its most expensive drug used by 46,000 arthritis sufferers
Health  bosses have signed a deal to save £300million a year by using cheaper versions of a costly arthritis drug. More than 46,000 English patients take adalimumab, which had been £400million a year. (Source: the Mail online | Health)
Source: the Mail online | Health - November 26, 2018 Category: Consumer Health News Source Type: news

NHS ditches its most expensive drug used by 46,000 arthritis sufferers in bid to save £300million
Health  bosses have signed a deal to save £300million a year by using cheaper versions of a costly arthritis drug. More than 46,000 English patients take adalimumab, which had been £400million a year. (Source: the Mail online | Health)
Source: the Mail online | Health - November 26, 2018 Category: Consumer Health News Source Type: news

NHS set to save £300 million on NHS’s highest drug spend
Biosimilar versions of adalimumab to be introduced Related items fromOnMedica Cancer Drugs Fund ‘wasteful and harmful’ The medicine price debate Drug prices may rise for NHS after Brexit NHS saves £324m by switching to cheaper medicines (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 26, 2018 Category: UK Health Source Type: news

Paradoxical Development of Panuveitis and Granulomatous Interstitial Lung Disease Associated with Adalimumab Therapy for Psoriasis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 19, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Medical News Today: Differences between Enbrel and Humira
Enbrel and Humira are medications that doctors prescribe to treat rheumatoid arthritis and other conditions. Both help lower inflammation in the joints and are similar, regarding their available forms, storage, and costs. Learn more about Enbrel and Humira, and which might be the most appropriate, here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 13, 2018 Category: Consumer Health News Tags: Rheumatoid Arthritis Source Type: news

FDA approves Novartis' copy of AbbVie bestseller Humira
The U.S. Food and Drug Administration (FDA) has approved Novartis AG's copy of Humira, the world's bestselling prescription medicine developed by U.S.-based AbbVie Inc, the agency's website showed on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - October 31, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Hyrimoz (adalimumab-adaz), a Biosimilar to Humira
Holzkirchen, Germany, October 31, 2018 - Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, Hyrimoz (adalimumab-adaz). The FDA granted... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 31, 2018 Category: Drugs & Pharmacology Source Type: news

A Humira Prescription Costs $38,000 A Year Because Our Patent System Is Being Abused
America's seniors deserve better. (Source: Science - The Huffington Post)
Source: Science - The Huffington Post - October 28, 2018 Category: Science Source Type: news

New JAK1 Agent Beats Humira in Rheumatoid Arthritis
(MedPage Today) -- Thrombotic events balanced between upadacitinib, adalimumab, and placebo (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - October 22, 2018 Category: Rheumatology Source Type: news

AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Fresenius Kabi
Agreements Provide Non-Exclusive License to Fresenius Kabi for HUMIRA-Related Intellectual Property in the U.S. Effective September 30, 2023, and in Other Markets on Different Dates Fresenius Kabi Acknowledges Validity of AbbVie's Intellectual Property ... Biopharmaceuticals, Litigation, Licensing AbbVie, Fresenius Kabi, HUMIRA, adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 18, 2018 Category: Pharmaceuticals Source Type: news

AbbVie settles Humira biosimilar dispute with Fresenius Kabi
U.S. drugmaker AbbVie Inc said on Thursday it has settled a patent dispute regarding its Humira biosimilar with Fresenius Kabi Oncology Ltd and will grant the Germany-based company non-exclusive marketing rights for the drug. (Source: Reuters: Health)
Source: Reuters: Health - October 18, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Amgen launches AMGEVITATM (Biosimilar Adalimumab) In markets across Europe
Amgen (NASDAQ:AMGN) announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of (Source: World Pharma News)
Source: World Pharma News - October 17, 2018 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU
Rival versions of the world ’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Biosimilars set to benefit patients and the NHS
Today marks the European patent expiry for the biologic Adalimumab (Humira), which is prescribed in hospitals for conditions including rheumatoid arthritis, inflammatory bowel disease and psoriasis. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - October 16, 2018 Category: Drugs & Pharmacology Source Type: news

Adalimumab (Humira)
Title: Adalimumab (Humira)Category: MedicationsCreated: 10/16/2018 12:00:00 AMLast Editorial Review: 10/16/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 16, 2018 Category: Drugs & Pharmacology Source Type: news

Amgen Launches AMGEVITA ™ (Biosimilar Adalimumab) In Markets Across Europe
First Inflammation Biosimilar From Amgen's Portfolio to Launch in Europe THOUSAND OAKS, Calif., Oct. 15, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidenc...
Source: Amgen News Release - October 16, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

‘Patients Deserve to Know’: Trump Administration Wants Drug Commercials to Show Prices
TRENTON, N.J. — The federal government said Monday that it wants to force drugmakers to disclose prices for prescription medicines in their TV commercials. The drug industry’s main trade group said drug companies are only willing to disclose the prices on their websites, not in commercials, and they’ll start doing that next spring. Health and Human Services Secretary Alex Azar unveiled a proposal that would apply to all brand-name drugs covered by the Medicare and Medicaid programs, which is most medicines. “Patients deserve to know what a given drug could cost when they’re being told about th...
Source: TIME: Health - October 16, 2018 Category: Consumer Health News Authors: LINDA A. JOHNSON / AP Tags: Uncategorized Healthcare onetime Source Type: news

Rivals line up to take on world’s best-selling drug
As the European patent on AbbVie’s Humira expires, biosimilars are ready to target $20bn market (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 14, 2018 Category: Pharmaceuticals Source Type: news

Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
Sandoz, a Novartis division and the global leader in biosimilars, announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz® (adalimumab)[1] for reference medicine Humira®* (adalimumab). (Source: World Pharma News)
Source: World Pharma News - October 12, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Abbvie settles Humira patent disputes with Novartis unit
Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG, granting it a non-exclusive license to manufacture and sell a copycat version of blockbuster drug, Humira. (Source: Reuters: Health)
Source: Reuters: Health - October 11, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

3 Evolutionary Scientists Win Nobel Chemistry Prize
(STOCKHOLM) — Three researchers who “harnessed the power of evolution” to produce enzymes and antibodies that have led to a new best-selling drug and biofuels won the Nobel Prize in chemistry on Wednesday. Frances Arnold of the California Institute of Technology was awarded half of the 9-million-kronor ($1.01 million) prize, while the other half will be shared by George Smith of the University of Missouri and Gregory Winter of the MRC molecular biology lab in Cambridge, England. The Royal Swedish Academy of Sciences, which chose the winners, said Arnold, 62, conducted the first directed evolution of enzym...
Source: TIME: Science - October 3, 2018 Category: Science Authors: JIM HEINTZ and DAVID KEYTON / AP Tags: Uncategorized nobel prize onetime Source Type: news

EU Approves Fifth Copy of AbbVie's $18 Bln Drug Humira EU Approves Fifth Copy of AbbVie's $18 Bln Drug Humira
Europe has approved a fifth copy of AbbVie's $18-billion-a-year biologic drug Humira (adalimumab) – the world's best-selling prescription medicine – ramping up competition among makers of less-expensive biotech drugs.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 21, 2018 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

Mylan to launch Humira biosim in Europe
Mylan and Fujifilm Kyowa Kirin Biologics announced that the European Commission has granted marketing authorization for Hulio, a biosimilar to AbbVie's Humira. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 21, 2018 Category: Pharmaceuticals Source Type: news

California Sues Drug Maker AbbVie for Allegedly Paying Doctors to Prescribe Humira
A lawsuit filed Tuesday in California claims that pharmaceutical company AbbVie used cash, gifts, and services to induce doctors to overprescribe the widely used drug Humira, ignoring the medicine's potentially lethal side effects. Speaking in a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 20, 2018 Category: General Medicine Source Type: news

EU approves fifth biosimilar for blockbuster Humira drug
Mylan (NSDQ:MYL) and Fujifilm Kyowa Kirin Biologics said today that the European Commission gave the companies marketing authorization for Hulio, a biosimilar to AbbVie‘s (NYSE:ABBV) billion-dollar Humira product. Mylan said it plans to launch Hulio across particular markets in Europe on or after Oct. 16. The drug is the fifth product authorized by the EC as a biosimilar for AbbVie’s Humira. There is no biosimilar for Humira in the U.S. Get the full story at our sister site, Drug Delivery Business News. The post EU approves fifth biosimilar for blockbuster Humira drug appeared first on MassD...
Source: Mass Device - September 20, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Pharmaceuticals Regulatory/Compliance Wall Street Beat AbbVie fujifilm Mylan Source Type: news

Morning Break:'Cool' E-Cig Warnings; Humira Kickback Suit; Kidney Stones as Art?
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 20, 2018 Category: American Health Source Type: news

EU approves fifth copy of AbbVie's $18 billion drug Humira
Europe has approved a fifth copy of AbbVie's $18-billion-a-year biologic drug Humira – the world's best-selling prescription medicine – ramping up competition among makers of less-expensive biotech drugs. (Source: Reuters: Health)
Source: Reuters: Health - September 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Mylan, Fujifilm win EU okay for copy of AbbVie's Humira
Mylan and Fujifilm Kyowa Kirin Biologics said on Thursday they had won European approval to market a cheaper copy of AbbVie's $18-billion-a-year biologic drug Humira, the world's best-selling prescription medicine. (Source: Reuters: Health)
Source: Reuters: Health - September 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Health Highlights: Sept. 20, 2018
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: California Sues Drug Maker AbbVie for Allegedly Paying Doctors to Prescribe Humira A lawsuit filed Tuesday in California claims that... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 20, 2018 Category: General Medicine Source Type: news

Suit targets AbbieVie for alleged kickback scheme
Regulators in California are suing AbbieVie for an alleged kickback scheme that boosted prescriptions for its blockbuster medication, Humira. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 19, 2018 Category: Pharmaceuticals Source Type: news

California Lawsuit Claims AbbVie Paid Doctors to Prescribe Humira
WEDNESDAY, Sept. 19, 2018 -- A lawsuit filed Tuesday in California claims that pharmaceutical company AbbVie used cash, gifts, and services to induce doctors to overprescribe the widely used drug Humira (adalimumab), ignoring the medicine's... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 19, 2018 Category: Pharmaceuticals Source Type: news

AbbVie shares fall after being sued by California over Humira allegations
The California Insurance Commissioner is suing AbbVie Inc., claiming the Illinois drug giant "gave illegal kickbacks to health care providers to prescribe" its Humira rheumatoid arthritis drug. In his lawsuit, Insurance Commissioner Dave Jones alleged AbbVie (NYSE: ABBV) "has engaged in a far-reaching scheme including both 'classic' kickbacks — cash, meals, drinks, gifts, trips, and patient referrals — and more sophisticated ones — free and valuable professional goods and services to physicians… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 19, 2018 Category: Biotechnology Authors: Ben Miller Source Type: news

AbbVie shares fall after being sued over Humira allegations
The California Insurance Commissioner is suing AbbVie Inc., claiming the Illinois drug giant "gave illegal kickbacks to health care providers to prescribe" its Humira rheumatoid arthritis drug. In his lawsuit, Insurance Commissioner Dave Jones alleged AbbVie (NYSE: ABBV) "has engaged in a far-reaching scheme including both 'classic' kickbacks — cash, meals, drinks, gifts, trips, and patient referrals — and more sophisticated ones — free and valuable professional goods and services to physicians… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 19, 2018 Category: Biotechnology Authors: Ben Miller Source Type: news

Health Highlights: Sept. 19, 2018
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: California Sues Drug Maker AbbVie for Allegedly Paying Doctors to Prescribe Humira A lawsuit filed Tuesday in California claims that... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 19, 2018 Category: General Medicine Source Type: news

California Sues AbbVie Over Alleged Kickback Scheme for Humira California Sues AbbVie Over Alleged Kickback Scheme for Humira
The complaint was prompted by a'whistleblower'who said AbbVie allegedly hired nurses'nationwide'to represent themselves as patient advocates when they were really company ambassadors'hired to...keep patients on a dangerous drug at any cost,'according to the state's insurance commissioner.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 18, 2018 Category: Consumer Health News Tags: Rheumatology News Source Type: news

California sues maker of Humira for alleged kickbacks to doctors
California filed a lawsuit Tuesday accusing pharmaceutical giant AbbVie of illegally plying doctors with cash, gifts and services to prescribe Humira despite its potentially deadly complications. (Source: CBC | Health)
Source: CBC | Health - September 18, 2018 Category: Consumer Health News Tags: News/Health Source Type: news

California insurance regulator sues AbbVie alleging Humira kickbacks
Insurance Commissioner Dave Jones on Tuesday filed a complaint on behalf of the State of California against AbbVie Inc, alleging the drugmaker gave illegal kickbacks to healthcare providers to prescribe its blockbuster drug, Humira. (Source: Reuters: Health)
Source: Reuters: Health - September 18, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

California: Drugmaker paid doctors to overprescribe Humira
California has filed a lawsuit accusing pharmaceutical giant AbbVie of illegally plying doctors with cash, gifts and services to prescribe one of the world's biggest selling drugs (Source: ABC News: Health)
Source: ABC News: Health - September 18, 2018 Category: Consumer Health News Tags: Health Source Type: news

California sues AbbVie over alleged Humira kickbacks
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 18, 2018 Category: Pharmaceuticals Source Type: news

Cyltezo-Phase III -in Psoriasis
Biosimilar Cyltezo ® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasisData show that Cyltezo © (adalimumab- adbm) and Humira®* have similar efficacy, safety and immunogenicity in people with moderate-to-severe chronic plaque psoriasis1At week 16, the study met the primary endpoint, demonstrating clinical equivalence to Humira ®1Data will be presented at the European Association of Dermatology and Venereology Annual Meeting (EADV 2018) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 12, 2018 Category: Research Source Type: news

Europe ready to cash in on cheap copies of AbbVie biotech drug
U.S. drugmaker AbbVie ABBV.N faces a crunch moment in Europe in mid-October when less-expensive copies of its $18-billion-a-year biologic drug Humira – the world's best-selling prescription medicine – hit the market. (Source: Reuters: Health)
Source: Reuters: Health - August 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Sarilumab Monotherapy vs Adalimumab Monotherapy in RA Sarilumab Monotherapy vs Adalimumab Monotherapy in RA
What benefits might sarilumab monotherapy offer over adalimumab monotherapy in the treatment of rheumatoid arthritis?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 16, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Longer-Term Safety and Efficacy of Adalimumab in Axial Spondyloarthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - August 15, 2018 Category: Orthopaedics Tags: Snapshot Source Type: news

Adalimumab Appears Safe for Treating Pediatric Patients With Autoimmune Disease Adalimumab Appears Safe for Treating Pediatric Patients With Autoimmune Disease
Adalimumab appears to be safe for treating pediatric patients with polyarticular juvenile idiopathic arthritis (JIA), enthesitis-related arthritis (ERA), psoriasis and Crohn's disease (CD), according to data from company-sponsored clinical trials.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 10, 2018 Category: Allergy & Immunology Tags: Pediatrics News Source Type: news

Planning for implementation of best value adalimumab
The Specialist Pharmacy Service is asking CCGs to prepare for the entry to market this October of adalimumab biosimilars. (Source: NHS Networks)
Source: NHS Networks - August 3, 2018 Category: UK Health Source Type: news

Mylan strikes Humira biosim delay deal with AbbVie
In an effort to protect its Humira patent, AbbVie signed an agreement to grant Mylan the rights to begin marketing its biosimilar in the United States. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 20, 2018 Category: Pharmaceuticals Source Type: news

Adalimumab May Help Maintain Remission in Non-Radiographic Axial Spondyloarthritis Adalimumab May Help Maintain Remission in Non-Radiographic Axial Spondyloarthritis
In patients with active non-radiographic axial spondyloarthritis (nr-axSpA) who achieved remission while taking adalimumab, researchers saw fewer flares among those who continued taking the drug than among those who stopped taking it.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - July 18, 2018 Category: Orthopaedics Tags: Rheumatology News Source Type: news